The new compound diabetes drug o'shuangning (R) was approved in China

Source: Sina Pharma 2017-04-05 bringer Ingelheim China and Lilly China announced that they have received the marketing license from the State Food and Drug Administration for o'shuangning ® Ornithine ® (liggliptin / metformin hydrochloride) is a single dose compound drug of DPP-4 inhibitor liggliptin and metformin, which can be used as an auxiliary treatment for diet control and exercise, and to improve blood glucose control level in adult type 2 diabetic patients suitable for liggliptin and metformin treatment "I'm very glad that ornithine ® will soon benefit Chinese patients with type 2 diabetes." Professor Mu Yiming, chairman of the endocrinology branch of the Chinese Medical Association and director of the Endocrinology Department of the PLA General Hospital, said, "for patients with type 2 diabetes who have poor metformin control, choose the compound drug of liggliptin and metformin The two mechanisms of hypoglycemic ingredients complement each other, which can provide more effective and lasting blood glucose control After oral administration, about 95% of the gligliptin component in ornithine ® is excreted through bile and intestinal tract, and only about 5% is excreted through kidney, so there is no additional burden on kidney 1-3 "Brigham Ingelheim Lilly diabetes alliance welcomes a new member of the o'donning family in China!" Dr Maarten hendriks, vice president of medicine for Greater China, said "With the development of diabetes, many patients with diabetes need more than one drug to fully manage the disease Orbinine ® is a simple compound single drug, which can reduce the number of tablets taken by patients, thus increasing the compliance of patients, and the improvement of compliance also helps to further improve blood glucose control " The dosage form of ornithine ® to be launched in China is 2.5mg/850mg of gligligliptin hydrochloride metformin, which is the first compound tablet launched by the bringlingham Lilly diabetes alliance in China after the DPP-4 inhibitor of ornithine ® (gliptin) The follow-up products of blingham Lilly diabetes alliance also include the SGLT2 inhibitor, englerine, which has been listed in many countries, such as the European Union and the United States Englerine is the only diabetes drug in the United States that can be used to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease, and the drug specifications in other countries include the heart Risk reduction data of vascular death 4-17, the drug has been submitted to the market in China.